Symptom-onset treatment for women with premenstrual dysphoric disorder

Journal of Clinical Psychopharmacology
Kimberly A YonkersHeather B Howell

Abstract

Symptoms of premenstrual dysphoric disorder (PMDD) respond to serotonin reuptake inhibitors when treatment is limited to 14 days of the menstrual cycle. Many women have less than a week of symptoms, and shorter treatment intervals would further reduce medication exposure and costs. Twenty women with PMDD were randomly assigned to either paroxetine CR or placebo for 1 cycle and crossed over to the other condition for a second cycle. Subjects initiated treatment when premenstrual symptoms began and stopped within 3 days of beginning menses. Women took capsules for an average of 9 days (range, 3-15 days), including the first few days of menses. Moderate "PMDD level" symptoms occurred in 1 subject (6%) for 2 days and 4 subjects (24%) for 1 day before starting paroxetine or placebo. Daily Record of Severity of Problems scores were lower in the paroxetine group compared with the placebo group, although the differences were not statistically significant. However, the mean on-treatment Inventory of Depressive Symptomatology (clinician-rated) score for the paroxetine group was 17.9 +/- 8.3 compared with 31.5 +/- 11.2 in the placebo group (adjusted mean difference = 13.6, P = 0.009). Response (Clinical Global Impressions Scale score of 1...Continue Reading

References

Sep 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C SundbladE Eriksson
May 1, 1996·Psychological Medicine·A J RushM H Trivedi
Oct 29, 1997·The Journal of Clinical Psychiatry·U Halbreich, J W Smoller
May 29, 2000·The British Journal of Psychiatry : the Journal of Mental Science·D MichelsonR G Tepner
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Mar 23, 2005·Journal of Affective Disorders·Teri PearlsteinJohn A Gillespie
Mar 23, 2005·Journal of Affective Disorders·Kimberly A YonkersJohn A Gillespie

❮ Previous
Next ❯

Citations

Mar 20, 2012·Journal of Clinical Psychology in Medical Settings·Maria KleinstäuberWolfgang Hiller
Jul 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mikael LandénElias Eriksson
Apr 18, 2009·Harvard Review of Psychiatry·Joanne CunninghamElias Eriksson
Aug 26, 2009·Women's Health·Laura J MillerRenu Gupta
Oct 29, 2013·Women's Health·Andrea J Rapkin, Erin I Lewis
Apr 9, 2008·Lancet·Kimberly Ann YonkersElias Eriksson
Sep 26, 2015·Journal of Affective Disorders·Renske C BosmanMarije aan het Rot
May 9, 2012·Depression and Anxiety·Emma M SteinbergPeter J Schmidt
Sep 18, 2015·Current Psychiatry Reports·Liisa Hantsoo, C Neill Epperson
Jun 27, 2013·Journal of Affective Disorders·Eynav E AccorttJohn J B Allen
Jan 29, 2008·Expert Opinion on Pharmacotherapy·Andrea J Rapkin, Sharon A Winer
Aug 2, 2011·Journal of Affective Disorders·Meir SteinerRoger Haskett
Aug 24, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Alexandre SchiolaJean Endicott
Jun 8, 2013·The Cochrane Database of Systematic Reviews·Jane MarjoribanksKatrina Wyatt
Sep 10, 2015·Journal of Psychiatric Practice·Shalini Maharaj, Kenneth Trevino
Aug 7, 2010·Expert Opinion on Pharmacotherapy·Ellen W Freeman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.